-+ 0.00%
-+ 0.00%
-+ 0.00%

Oncolytics Biotech wins new US manufacturing patent for pelareorep, protection through 2044

PUBT·06/16/2026 13:01:41
Listen to the news
Oncolytics Biotech wins new US manufacturing patent for pelareorep, protection through 2044
  • Oncolytics Biotech secured a new U.S. patent covering its commercial-scale manufacturing process for pelareorep, with protection expected to run into 2044.
  • A separate method-of-use patent application for pelareorep as an immunotherapy remains under review, with potential protection into 2046 if issued.
  • Additional patent applications are planned in 2026 to expand protection for pelareorep across more uses and combination approaches.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Oncolytics Biotech Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606160900PRIMZONECNPR____9747578) on June 16, 2026, and is solely responsible for the information contained therein.